- Home
- QSI vs GOSS Comparison
QSI vs GOSS Comparison
Compare QSI & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- GOSS
- Stock Information
- Founded
- QSI 2013
- GOSS 2015
- Country
- QSI United States
- GOSS United States
- Employees
- QSI N/A
- GOSS N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- GOSS Health Care
- Exchange
- QSI Nasdaq
- GOSS Nasdaq
- Market Cap
- QSI 219.8M
- GOSS 262.5M
- IPO Year
- QSI N/A
- GOSS 2019
- Fundamental
- Price
- QSI $2.11
- GOSS $1.25
- Analyst Decision
- QSI Strong Buy
- GOSS Strong Buy
- Analyst Count
- QSI 3
- GOSS 3
- Target Price
- QSI $2.38
- GOSS $7.33
- AVG Volume (30 Days)
- QSI 8.4M
- GOSS 2.6M
- Earning Date
- QSI 08-06-2025
- GOSS 08-11-2025
- Dividend Yield
- QSI N/A
- GOSS N/A
- EPS Growth
- QSI N/A
- GOSS N/A
- EPS
- QSI N/A
- GOSS N/A
- Revenue
- QSI $3,443,000.00
- GOSS $124,590,000.00
- Revenue This Year
- QSI $77.57
- GOSS N/A
- Revenue Next Year
- QSI $251.34
- GOSS $91.14
- P/E Ratio
- QSI N/A
- GOSS N/A
- Revenue Growth
- QSI 167.94
- GOSS N/A
- 52 Week Low
- QSI $0.61
- GOSS $0.66
- 52 Week High
- QSI $5.77
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- QSI 65.03
- GOSS 49.48
- Support Level
- QSI $1.87
- GOSS $1.20
- Resistance Level
- QSI $2.14
- GOSS $1.33
- Average True Range (ATR)
- QSI 0.14
- GOSS 0.10
- MACD
- QSI 0.02
- GOSS -0.02
- Stochastic Oscillator
- QSI 93.65
- GOSS 18.37
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.